Yorktown Management & Research Co Inc Takes Position in TransMedics Group, Inc. $TMDX

Yorktown Management & Research Co Inc acquired a new stake in TransMedics Group, Inc. (NASDAQ:TMDX) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 3,500 shares of the company’s stock, valued at approximately $393,000.

A number of other institutional investors have also recently added to or reduced their stakes in TMDX. Opal Wealth Advisors LLC acquired a new stake in TransMedics Group in the second quarter valued at $26,000. Salomon & Ludwin LLC acquired a new stake in shares of TransMedics Group in the third quarter valued at about $28,000. Sound Income Strategies LLC bought a new position in shares of TransMedics Group during the second quarter worth about $48,000. Elevation Point Wealth Partners LLC acquired a new position in shares of TransMedics Group in the second quarter worth approximately $48,000. Finally, First Horizon Corp acquired a new stake in TransMedics Group during the 3rd quarter valued at approximately $43,000. 99.67% of the stock is owned by institutional investors.

Insider Activity at TransMedics Group

In other news, Director David Weill sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $138.64, for a total transaction of $693,200.00. Following the completion of the sale, the director owned 12,134 shares in the company, valued at $1,682,257.76. This trade represents a 29.18% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Anil P. Ranganath sold 3,000 shares of the stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $145.22, for a total value of $435,660.00. Following the transaction, the insider directly owned 13,955 shares of the company’s stock, valued at approximately $2,026,545.10. This trade represents a 17.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 13,062 shares of company stock valued at $1,797,634 over the last quarter. 7.00% of the stock is currently owned by insiders.

TransMedics Group Stock Down 0.2%

TransMedics Group stock opened at $143.37 on Friday. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $156.00. The company has a debt-to-equity ratio of 1.43, a quick ratio of 7.13 and a current ratio of 7.69. The firm’s 50-day simple moving average is $130.87 and its 200 day simple moving average is $122.58. The stock has a market cap of $4.90 billion, a PE ratio of 58.04 and a beta of 2.03.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Wednesday, October 29th. The company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.29. TransMedics Group had a return on equity of 31.42% and a net margin of 16.20%.The company had revenue of $143.82 million during the quarter, compared to analyst estimates of $145.33 million. During the same period in the prior year, the company posted $0.12 earnings per share. TransMedics Group’s quarterly revenue was up 32.2% on a year-over-year basis. Research analysts predict that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

TMDX has been the subject of a number of analyst reports. Jefferies Financial Group started coverage on shares of TransMedics Group in a research note on Monday, October 13th. They set a “buy” rating and a $145.00 target price for the company. Weiss Ratings reissued a “hold (c)” rating on shares of TransMedics Group in a research report on Wednesday, October 8th. Zacks Research downgraded TransMedics Group from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Piper Sandler restated an “overweight” rating on shares of TransMedics Group in a research note on Monday, December 22nd. Finally, Morgan Stanley lifted their price objective on shares of TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a report on Tuesday, December 2nd. Six investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $144.25.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post?transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.